Scarica l'app Stockscreener
25.50
21.20%
4.46
Dopo l'orario di chiusura:
25.40
-0.10
-0.39%
Precedente Chiudi:
$21.04
Aprire:
$21.52
Volume 24 ore:
276.68K
Relative Volume:
2.00
Capitalizzazione di mercato:
$330.74M
Reddito:
$56.54M
Utile/perdita netta:
$-30.70M
Rapporto P/E:
-65.38
EPS:
-0.39
Flusso di cassa netto:
$-31.05M
1 W Prestazione:
+36.88%
1M Prestazione:
+32.95%
6M Prestazione:
+77.45%
1 anno Prestazione:
+112.50%
Intervallo 1D:
$21.48
$25.58
Intervallo di 1 settimana:
$18.69
$25.58
Portata 52W:
$10.14
$28.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Nome
Cidara Therapeutics Inc
Settore
Industria
Telefono
858-752-6170
Indirizzo
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Confronta CDTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
25.50 | 241.63M | 56.54M | -30.70M | -31.05M | -0.39 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-12 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-01-27 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-08 | Iniziato | Guggenheim | Buy |
| 2024-08-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Ripresa | H.C. Wainwright | Buy |
| 2021-09-22 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Iniziato | Aegis Capital | Buy |
| 2019-09-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-07-26 | Iniziato | Citigroup | Buy |
| 2017-04-21 | Iniziato | Raymond James | Strong Buy |
| 2017-04-17 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-04-11 | Ripresa | Wedbush | Outperform |
| 2017-02-22 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-22 | Aggiornamento | WBB Securities | Sell → Hold |
| 2016-12-21 | Ripresa | Leerink Partners | Outperform |
| 2016-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2016-09-23 | Downgrade | WBB Securities | Hold → Sell |
| 2015-10-09 | Aggiornamento | WBB Securities | Sell → Hold |
| 2015-05-11 | Iniziato | Jefferies | Buy |
| 2015-05-11 | Iniziato | Leerink Partners | Outperform |
| 2015-05-11 | Iniziato | Needham | Buy |
| 2015-05-11 | Iniziato | Wedbush | Outperform |
| 2015-04-23 | Iniziato | WBB Securities | Sell |
Mostra tutto
Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie
When (CDTX) Moves Investors should Listen - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Target Price Raised by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenh - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics price target raised to $50 from $35 at Guggenheim - TipRanks
Cidara Therapeutics to Host Virtual R&D Day to Discuss - GlobeNewswire
Revolutionary Once-Per-Year Universal Flu Prevention: Cidara Unveils Phase 2b Trial Updates at R&D Day - Stock Titan
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Cidara Therapeutics’ CD388 Progress and Challenges Highlighted in Earnings Call - MSN
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $35.00 - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, JMP Securities Analyst Says - Defense World
Guggenheim Raises Price Target for Cidara Therapeutics (CDTX) to $35.00 | CDTX Stock News - GuruFocus
StockNews.com Upgrades Cidara Therapeutics (NASDAQ:CDTX) to Sell - Defense World
Cidara Therapeutics (CDTX) Target Price Raised by JMP Securities - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised by JMP Securities | CDTX Stock News - GuruFocus
RBC Cuts Price Target on Cidara Therapeutics to $31 From $34, Keeps Outperform, Speculative Risk - marketscreener.com
Cidara Therapeutics (CDTX) Target Price Raised to $35 by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX) Sees Price Target Increase by Citizens JMP | CDTX Stock News - GuruFocus
Cidara Therapeutics: Q1 Earnings Snapshot - New Haven Register
Cidara Therapeutics Inc (CDTX) Q1 2025 Earnings Call Highlights: Promising Advances in ... - Yahoo Finance
Cidara Therapeutics Inc (CDTX) Q1 2025 Earnings Call Highlights: Promising Advances in Influenza Prevention Amid Financial Challenges - GuruFocus
Cidara Therapeutics Reports Q1 2025 Financial Results - TipRanks
CDTX Targets Key Data Release for Influenza Treatment by Mid-202 - GuruFocus
Cidara Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CDTX Targets Key Data Release for Influenza Treatment by Mid-2025 | CDTX Stock News - GuruFocus
Cidara Therapeutics reports Q1 EPS ($1.66) vs. ($2.28) last year - TipRanks
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | CDTX Stock News - GuruFocus
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - The Manila Times
(CDTX) Investment Report - news.stocktradersdaily.com
Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate (CDTX) - Seeking Alpha
Nicole Davarpanah named Cidara CMO - The Pharma Letter
Candidiasis Pipeline: 15+ Key Innovators Advancing - openPR.com
Cidara Therapeutics (CDTX) Announces Key Leadership Promotions | - GuruFocus
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Cidara Therapeutics Names Nicole Davarpanah as Chief Medical Officer - marketscreener.com
Cidara Therapeutics (CDTX) Announces Key Leadership Promotions | CDTX Stock News - GuruFocus
Cidara Therapeutics appoints new CMO and SVP By Investing.com - Investing.com India
Cidara Therapeutics appoints new CMO and SVP - Investing.com
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development - The Manila Times
Cidara Therapeutics Announces Promotion of Nicole - GlobeNewswire
Cidara Therapeutics (NASDAQ:CDTX) Earns Market Outperform Rating from JMP Securities - Defense World
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice - Yahoo Finance
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference - GlobeNewswire
Cantor Fitzgerald raises Cidara stock to Overweight - MSN
JMP maintains $46 target on Cidara stock ahead of Phase 2b results - Investing.com Canada
Cidara Therapeutics Inc Azioni (CDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cidara Therapeutics Inc Azioni (CDTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
| Sandison Taylor | Chief Medical Officer |
Sep 11 '24 |
Sale |
11.64 |
924 |
10,752 |
23,067 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
| Stein Jeffrey | President & CEO |
Jun 07 '24 |
Buy |
13.21 |
8,000 |
105,680 |
24,580 |
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):